Microbiome & NASH - partners in crime driving progression of fatty liver disease.
[Microbiome &NASH - partners in crime driving progression of fatty liver disease]. Z Gastroenterol. 2019 Jul;57(7):871-882 Authors: Wree A, Geisler LJ, Tacke F Abstract Along with the increasing prevalence of obesity, metabolic syndrome and type 2 diabetes, non-alcoholic fatty liver disease (NAFLD) is rapidly increasing and poses a major challenge for gastroenterologists. Many studies have demonstrated that the microbiome is closely associated with the progression of nutrition-related diseases, especially of fatty liver disease. Changes in the quantity and quality of the intestinal flora, commonly referred to as dysbiosis, result in altered food metabolism, increased permeability of the intestinal barrier ("leaky gut") and consecutive inflammatory processes in the liver. This favors both the progression of obesity and metabolic disorders as well as NAFLD towards non-alcoholic steatohepatitis (NASH), hepatic fibrosis, cirrhosis and hepatocellular carcinoma (HCC). Important molecular mechanisms include microbial metabolites, microbial and endogenous signaling substances (so-called PAMPs/DAMPs) as well as bile acids. Essential cellular mechanisms include immune cells in the gut and liver, especially macrophages and Kupffer cells, as well as intestinal epithelial cells and hepatocytes as central regulators of metabolism. In this review article, we briefly summarize the relevant species of the human microbiome, describe the microbial analytics, ...
This study identifies patterns of alcohol consumption in youth and investigates how these patterns vary across schools and whether individual- a...
This study aimed to review chara cteristics of multicultural Asian diabetic patients presenting to tertiary care with peripheral vascular complications and subsequent intervention rates and outcomes.
The objective of this study was to review the outcomes after split-thickness skin grafting (SSG) of patients with peripheral artery disease and diabetic foot wounds in an Asian population.
Diabetic foot ulcer (DFU) is a major health problem and remains a major cause of amputation across the world. Critical assessment of the relationship between peripheral artery disease, revascularization, and healing of DFU was performed. A new therapy has been claimed to prevent major amputations in advanced DFU. The intralesional injection of recombinant human epidermal growth factor (EGF) should often lead to satisfactory outcomes. The purpose of our study was to demonstrate the advantage of the combination of revascularization and EGF local infiltration in accelerating healing of DFU.
CONCLUSIONS: These data provide health care providers with predicted ranges of liver enzymes in patients with hepatocellular or cholestatic liver disease and may thereby help to identify patients with concurrent forms of liver disease. PMID: 31628070 [PubMed - as supplied by publisher]
CONCLUSIONS: This study provides evidence that GRα expression was negatively regulated by miR-124a, which primarily determines the extent of acquired glucocorticoid resistance in ACLF. PMID: 31628069 [PubMed - as supplied by publisher]
Authors: Polyzos SA, Hawa G, Jungwirth T, Karabouta Z, Kountouras J PMID: 31628635 [PubMed - as supplied by publisher]
How accurate is the aldosterone-to-active renin ratio in diagnosing primary aldosteronism?Journal of the Endocrine Society
What knowledge have we gained regarding the presentation and management of renal cell carcinoma in young patients?Current Opinion in Urology
Roche today announced that the Phase III IMbrave150 study, evaluating Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) as a treatment for people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy, met both of its co-primary endpoints demonstrating statistically significant and clinically meaningful improvements i n overall survival (OS) and progression-free survival (PFS) compared with standard-of-care sorafenib.
More News: Alcoholism | Bile | Cancer & Oncology | Carcinoma | Cirrhosis | Diabetes | Diabetes Type 2 | Eating Disorders & Weight Management | Endocrinology | Epithelial Cancer | Fatty Liver Disease (FLD) | Gastroenterology | Hepatocellular Carcinoma | Liver | Liver Cancer | Liver Disease | Metabolic Syndrome | Non-alcoholic Fatty Liver Diseases (NAFLD) | Nutrition | Obesity | Study | Urology & Nephrology